Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Tw...

Full description

Bibliographic Details
Main Authors:	John N. Shumar, Abhimanyu Chandel, Christopher S. King
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Journal of Clinical Medicine
Subjects:	progressive fibrosing interstitial lung disease pulmonary fibrosis pirfenidone nintedanib interstitial lung disease IPF
Online Access:	https://www.mdpi.com/2077-0383/10/11/2285

Similar Items

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
by: Sebastiano Emanuele Torrisi, et al.
Published: (2019-11-01)

Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage
by: Laurens J. De Sadeleer, et al.
Published: (2020-06-01)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
by: Carlo Albera, et al.
Published: (2021-09-01)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01)

Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome
by: Ana Catarina Duarte, et al.
Published: (2019-04-01)

Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
by: Kazuki Nakashima, et al.
Published: (2021-01-01)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
by: Gian Luca Erre, et al.
Published: (2021-01-01)

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
by: Mehdi Mirsaeidi, et al.
Published: (2019-10-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
by: Toyoshi Yanagihara, et al.
Published: (2020-01-01)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
by: Tinne Goos, et al.
Published: (2021-03-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
by: Ulrike Schmid, et al.
Published: (2021-07-01)

Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response
by: Willis S. Bowman, et al.
Published: (2021-05-01)

Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases
by: Julie Tanguy, et al.
Published: (2021-08-01)

Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
by: Yoichiro Aoshima, et al.
Published: (2021-02-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

Case report: new development of fibrosing interstitial lung disease triggered by HIV-related pneumocystis pneumonia
by: Tetsuya Suzuki, et al.
Published: (2019-03-01)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01)

Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
by: Paola Faverio, et al.
Published: (2021-09-01)

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
by: Zarir F Udwadia, et al.
Published: (2015-01-01)

Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival
by: Eniko Barczi, et al.
Published: (2020-07-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01)

Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis
by: Cui, S., et al.
Published: (2022)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
by: Hongseok Yoo, et al.
Published: (2021-01-01)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
by: Chung, M.P, et al.
Published: (2022)

Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients
by: Benjamin Bondue, et al.
Published: (2019-01-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Progression of fibrosing interstitial lung disease
by: Alyson W. Wong, et al.
Published: (2020-01-01)

Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification
by: Monica Palermo, et al.
Published: (2021-01-01)

Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-08-01)

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)
by: Adelle S. Jee, et al.
Published: (2017-05-01)

Current Diagnosis and Management of Hypersensitivity Pneumonitis
by: Paolo Maria Leone, M.D., et al.
Published: (2020-04-01)

Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature
by: Renata Ferrarotto, et al.
Published: (2011-12-01)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
by: Toshiyuki Sumi, et al.
Published: (2021-03-01)